Our news
Neophore appoints Michael Shih as Chief Executive Officer
º£½ÇÂÒÂ× appoints Michael Shih as Chief Executive Officer • Highly experienced corporate development leader with a track record of international p…
º£½ÇÂÒÂ× closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
º£½ÇÂÒÂ× closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb Additional funding will be used to explore…
º£½ÇÂÒÂ× presented preclinical data from our PMS2 program at the AACR Annual Meeting, San Diego, 5 - 10 April 2024.
The º£½ÇÂÒÂ× team attended the American Association for Cancer Research Annual Meeting in San Diego, 5 - 10 April 2024. In collaboration with The…
º£½ÇÂÒÂ× raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline
º£½ÇÂÒÂ× raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline • Italian investors, NE…
Other news
CEO Jeff Roix spoke to BioCentury about how º£½ÇÂÒÂ× Ltd is developing small molecules to inhibit DNA mismatch repair (MMR) and create a pool of…
APM Health: Interview with CEO, Jeff Roix
Scrip Emerging company profile: UK-based º£½ÇÂÒÂ×, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company…